ReachMDLung Cancer Pill Cuts Death Risk by Half in New Study

Adjuvant Tagrisso should continue to be the standard of care for patients with EGFR-driven lung cancer who are at a high risk of recurrence after surgery, according to the findings of the new study.

Delving into the potency of targeted cancer therapy, recent study results suggest a remarkable surge in survival rates for early-stage lung cancer patients who incorporate Tagrisso (osimertinib) into their post-surgery treatment regimen.

Key Points:

• The study involved 682 patients with non-small-cell lung cancer (NSCLC) having mutated epidermal growth factor receptor (EGFR) genes.
• Post-surgery, patients were given either a placebo or an 80mg dose of Tagrisso daily.
• After three years, patients who took Tagrisso exhibited a 51% lower risk of death.
• The five-year survival rate for patients using Tagrisso was 88%, compared to 78% for placebo patients.

Additional Points:

• The FDA approval for Tagrisso for early-stage lung cancer was based on disease-free survival (DFS)
• The approval of Tagrisso as an adjuvant therapy for early-stage lung cancer came in 2020, following its initial approval in 2018 for advanced lung cancer.

Conclusion:

• The new results emphasize the potential of Tagrisso as a standard care protocol for EGFR-driven lung cancer patients at high risk of recurrence after surgery.

Further Reading

• New Research Sheds Light on a Surprising Connection Between COVID-19 and Cancer RegressionDecember 3, 2024
• What Is Bladder Cancer?December 3, 2024
• Big Year in SCLC: “Unprecedented” Results Lead to New Standard of CareDecember 3, 2024